Novavax Inc. [NASDAQ: NVAX] surged by $10.79 during the normal trading session on Wednesday and reaching a high of $214.50 during the day while it closed the day at $209.64. The company report on June 9, 2021 that Novavax to Host Maryland Governor Larry Hogan at Site of Future Novavax Vaccines Innovation Campus and Global Headquarters.
Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, will host Maryland Governor Larry Hogan at the site of the company’s planned Vaccines Innovation Campus and global headquarters in Gaithersburg on Thursday, June 10 at 9:30 AM ET. Additional guests will include state, regional and local officials.
A tour, overview of the future facility and press briefing will be led by Novavax’ President and Chief Executive Officer, Stanley C. Erck, and President of Research and Development, Greg Glenn, M.D. The event follows the approval on June 7 by Gaithersburg Mayor Jud Ashman and the City Council of the company’s plans, which will add R&D and manufacturing capacity at the site, as well as offices. The event will highlight the company’s growing footprint in Maryland’s bioinnovation corridor. Renderings of the planned 180,000 square foot global corporate headquarters and future campus will also be shared.
Novavax Inc. stock has also gained 22.38% of its value over the past 7 days. However, NVAX stock has inclined by 21.53% in the 3 months of the year. Over the past six months meanwhile, it has gained 70.27% and gained 88.00% year-on date.
The market cap for NVAX stock reached $14.74 billion, with 73.03 million shares outstanding and 69.32 million shares in the current float. Compared to the average trading volume of 3.50M shares, NVAX reached a trading volume of 4869926 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Novavax Inc. [NVAX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVAX shares is $288.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVAX stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Novavax Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 12, 2021. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on December 14, 2020, representing the official price target for Novavax Inc. stock. Previously, the target price had yet another raise from $132 to $290, while H.C. Wainwright kept a Buy rating on NVAX stock.
The Average True Range (ATR) for Novavax Inc. is set at 16.11, with the Price to Sales ratio for NVAX stock in the period of the last 12 months amounting to 16.03. The Price to Book ratio for the last quarter was 14.73, with the Price to Cash per share for the same quarter was set at 28.41. Price to Free Cash Flow for NVAX in the course of the last twelve months was 25.62 with Quick ratio for the last quarter at 1.90.
NVAX stock trade performance evaluation
Novavax Inc. [NVAX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 22.38. With this latest performance, NVAX shares gained by 30.62% in over the last four-week period, additionally plugging by 70.27% over the last 6 months – not to mention a rise of 356.43% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVAX stock in for the last two-week period is set at 68.03, with the RSI for the last a single of trading hit 80.05, and the three-weeks RSI is set at 60.83 for Novavax Inc. [NVAX]. The present Moving Average for the last 50 days of trading for this stock 179.84, while it was recorded at 192.05 for the last single week of trading, and 152.32 for the last 200 days.
Novavax Inc. [NVAX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Novavax Inc. [NVAX] shares currently have an operating margin of -87.05. Novavax Inc.’s Net Margin is presently recorded at -87.94.
Return on Total Capital for NVAX is now -65.98, given the latest momentum, and Return on Invested Capital for the company is -73.12. Return on Equity for this stock declined to -189.60, with Return on Assets sitting at -47.65. When it comes to the capital structure of this company, Novavax Inc. [NVAX] has a Total Debt to Total Equity ratio set at 76.83. Additionally, NVAX Total Debt to Total Capital is recorded at 43.45, with Total Debt to Total Assets ending up at 30.45. Long-Term Debt to Equity for the company is recorded at 59.35, with the Long-Term Debt to Total Capital now at 33.56.
Reflecting on the efficiency of the workforce at the company, Novavax Inc. [NVAX] managed to generate an average of -$528,772 per employee. Receivables Turnover for the company is 3.53 with a Total Asset Turnover recorded at a value of 0.54.Novavax Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.90 and a Current Ratio set at 1.90.
Earnings per share (EPS) analysis for Novavax Inc. [NVAX] stock
With the latest financial reports released by the company, Novavax Inc. posted -0.3/share EPS, while the average EPS was predicted by analysts to be reported at -0.42/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 28.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVAX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novavax Inc. go to 0.00%.
Novavax Inc. [NVAX]: Insider Ownership positions
There are presently around $8,930 million, or 58.20% of NVAX stock, in the hands of institutional investors. The top three institutional holders of NVAX stocks are: VANGUARD GROUP INC with ownership of 5,893,304, which is approximately 5.261% of the company’s market cap and around 0.20% of the total institutional ownership; BLACKROCK INC., holding 5,473,023 shares of the stock with an approximate value of $1.15 billion in NVAX stocks shares; and FMR LLC, currently with $1.0 billion in NVAX stock with ownership of nearly 173.671% of the company’s market capitalization.
Positions in Novavax Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 205 institutional holders increased their position in Novavax Inc. [NASDAQ:NVAX] by around 10,734,829 shares. Additionally, 199 investors decreased positions by around 6,441,035 shares, while 43 investors held positions by with 25,423,044 shares. The mentioned changes placed institutional holdings at 42,598,908 shares, according to the latest SEC report filing. NVAX stock had 103 new institutional investments in for a total of 3,542,330 shares, while 60 institutional investors sold positions of 1,945,830 shares during the same period.